Safety and efficacy of neoadjuvant chemotherapy with paclitaxel, carboplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma-Reference-Cited by-同舟云学术

Safety and efficacy of neoadjuvant chemotherapy with paclitaxel, carboplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma

Published:2024-05-10 Issue:8 Volume:29 Page:1133-1141
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Tanaka Ryoko,Ueki Yushi^ORCID,Ohshima Shusuke,Omata Jo,Yokoyama Yusuke,Takahashi Takeshi,Shodo Ryusuke,Yamazaki Keisuke,Ohtaki Kohei,Togashi Takafumi,Horii Arata

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10147-024-02545-9.pdf

Reference28 articles.

1. National Comprehensive Cancer Network. Head and neck cancers, version 2.2023. https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf Accessed 23 Aug 2023

2. Xiao R, Ward MC, Yang K et al (2018) Increased pathologic upstaging with rising time to treatment initiation for head and neck cancer: a mechanism for increased mortality. Cancer 124:1400–1414. https://doi.org/10.1002/cncr.31213. (PMID: 29315499)

3. Liao DZ, Schlecht NF, Rosenblatt G et al (2019) Association of delayed time to treatment initiation with overall survival and recurrence among patients with head and neck squamous cell carcinoma in an underserved urban population. JAMA Otolaryngol Head Neck Surg 145:1001–1009. https://doi.org/10.1001/jamaoto.2019.2414. (PMID: 31513264)

4. Schoonbeek RC, Zwertbroek J, Plaat BEC et al (2021) Determinants of delay and association with outcome in head and neck cancer: a systematic review. Eur J Surg Oncol 47:1816–1827. https://doi.org/10.1016/j.ejso.2021.02.029. (PMID: 33715909)

5. Rygalski CJ, Zhao S, Eskander A et al (2021) Time to surgery and survival in head and neck cancer. Ann Surg Oncol 28:877–885. https://doi.org/10.1245/s10434-020-09326-4